RE:GSK buys Bellus for 2B$ to challenge MERCK’s marketWhat is encouraging about this acquisition is that GSK wasn't waiting around to see how the Phase 3 goes. They wanted to take control of the product NOW...the read out isn't even until late 2024 at the earliest and they forecast approval in 2026. This is exactly the type of planning that goes into pharma acquisitions. The competition for a new product/revenue stream is fierce and so they want to move on a deal well in advance of FDA approval.